Tuesday was the biggest single-day M&A event in biopharma since the start of 2026. Eli Lilly committed up to $7.8 billion to acquire Centessa Pharmaceuticals
Two very different signals about where pharma is headed landed on the same day. Eli Lilly announced the largest AI drug discovery deal in the
The weekend delivered on both fronts. Rocket Pharma finally landed FDA approval for Kresladi after a two-year journey, marking the first gene therapy for severe
Wednesday told two dramatically different stories about the distance between clinical data and stock price. Sarepta Therapeutics surged 35% after reporting the first clinical results
The big pharma M&A machine keeps running. Merck announced a $6.7 billion acquisition of Terns Pharmaceuticals on Wednesday, adding TERN-701—an oral allosteric BCR::ABL1 inhibitor for
Monday will be remembered as the day T-cell engagers crossed from oncology curiosity into absolute autoimmune conviction. Gilead Sciences and Sanofi, on the exact same
Monday delivered a study in contrasts. Pfizer and Valneva’s Lyme disease vaccine demonstrated 73% efficacy in Phase 3—a clinically meaningful result by any standard—but a
Last week was the most consequential five-day stretch for biotech in 2026 so far. Four FDA approvals, a blockbuster Phase 3 readout, and a $3
Thursday delivered two of the quarter’s most consequential catalysts, and both landed exactly where the data said they would. Rhythm Pharmaceuticals secured FDA approval for
Thursday’s headlines underscore a biotech sector caught between transformative clinical milestones and escalating operational risks. BridgeBio delivered highly anticipated Phase 3 FORTIFY data for its
